# Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

> **NCT04368273** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** PD-1 antibody

## Key facts

- **NCT ID:** NCT04368273
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-08
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04368273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04368273, "Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04368273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*